At least seven companies debuted on Wall Street Thursday, including credit reporting agency TransUnion.
The biggest gainer was Glaukos, a developer of products and procedures to treat glaucoma. Its shares rose more than 70 percent.
Continue Reading Below
More about the seven companies, and how their stocks did on Thursday:
The credit-reporting agency provides consumer credit reports and other information to businesses. It also offers credit reports, as well as identity theft protection services, to consumers. The Chicago company raised $664.8 million after selling about 29.5 million shares for $22.50 a share. It will use the cash raised to buy back debt. TransUnion's shares, which are trading under the symbol "TRU" on the New York Stock Exchange, rose $2.83, or 12.6 percent, to $25.33 in afternoon trading Thursday.
The maker of equipment used by the plastics industry raised $285.7 million after selling 14.3 million shares at $20 per share. The Cincinnati-based company will use the money to pay down debt. Milacron Holdings Corp.'s shares, trading on the NYSE under the ticker symbol "MCRN," fell 36 cents, or 2 percent, to $19.64 in afternoon trading.
The New York company ships oil by sea. It raised $210 million after selling 15 million shares at $14 per share. It plans to use the money raised to pay down debt and to possibly purchase more ships. Its stock is trading on the NYSE under the symbol "GNRT." Gener8 Maritime Inc.'s shares fell $1.04, or 7.5 percent, to $12.96.
The company, based in Laguna Hills, California, is developing products and procedures to treat glaucoma, an eye disorder that can lead to vision loss. It raised $108 million after selling 6 million shares at $18 per share, and plans to use the money to pay for marketing costs and clinical studies. Glaukos Corp.'s stock is trading on the NYSE under the symbol "GKOS." It rose $12.84, or 71 percent, to $30.84 in afternoon trading.
The North Billerica, Massachusetts, company makes contrast agents that are injected into patients so that X-ray and MRI images can be seen clearly by doctors. It raised $65 million, after selling 10.8 million shares at $6 per share. It will use the money to pay down debt. Lantheus Holdings Inc.'s shares, trading on the Nasdaq exchange under the symbol "LNTH," rose 60 cents, or 10 percent, to $6.60 in afternoon trading.
The company develops drugs for rare diseases, such as Duchenne muscular dystrophy. It raised $60 million after selling 5 million shares at $12 per share. Catabasis, based in Cambridge, Massachusetts, plans to use the money raised for drug development. Catabasis Pharmaceuticals Inc.'s shares, trading on the Nasdaq exchange under the symbol "CATB," rose $1, or 8.3 percent, to $13 in afternoon trading.
The drug developer sells treatment to relieve aches, pain and discomfort in women's breast. The Menlo Park, California, company raised $10 million after selling more than 3.6 million shares at $2.75 per share. It plans to use the money raised for research, development and advertising. BioPharmX Corp.'s shares are trading on the NYSE MKT exchange under the symbol "BPMX." They fell 69 cents, or 21.2 percent, to $2.56 in afternoon trading.